Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06501339

Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia

Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole on Psychopathology and Cerebral Perfusion in Clozapine-resistant Schizophrenia: a Randomized, Double-blind Controlled Trial

Status
Not Yet Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
All India Institute of Medical Sciences, Bhubaneswar · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS. However, literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRS is lacking. The objective of the study is to compare the efficacy of M-ECT vs aripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions, cerebral perfusion, global functioning and cognitions in patients with CRS.

Conditions

Interventions

TypeNameDescription
PROCEDUREmaintenance ECTFrequency of weekly sessions for 1 month, then fortnightly for 5 months
DRUGAripiprazole tabletAripiprazole 10 mg in the morning throughout the study period

Timeline

Start date
2024-08-10
Primary completion
2025-10-31
Completion
2026-03-31
First posted
2024-07-15
Last updated
2024-07-16

Source: ClinicalTrials.gov record NCT06501339. Inclusion in this directory is not an endorsement.